CN106659738B - 阿尔茨海默病(ad)的治疗和预防 - Google Patents

阿尔茨海默病(ad)的治疗和预防 Download PDF

Info

Publication number
CN106659738B
CN106659738B CN201580029861.5A CN201580029861A CN106659738B CN 106659738 B CN106659738 B CN 106659738B CN 201580029861 A CN201580029861 A CN 201580029861A CN 106659738 B CN106659738 B CN 106659738B
Authority
CN
China
Prior art keywords
oxyhydroxide
administered
patient
amount
aluminum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580029861.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106659738A (zh
Inventor
M.曼德勒
A.施尼伯格
A.冯博宁
F.马特纳
W.施密特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advantage Medical Co ltd
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of CN106659738A publication Critical patent/CN106659738A/zh
Application granted granted Critical
Publication of CN106659738B publication Critical patent/CN106659738B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580029861.5A 2014-04-29 2015-04-29 阿尔茨海默病(ad)的治疗和预防 Active CN106659738B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166354.2 2014-04-29
EP14166355.9 2014-04-29
EP14166355 2014-04-29
EP14166354 2014-04-29
PCT/EP2015/059339 WO2015165966A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (2)

Publication Number Publication Date
CN106659738A CN106659738A (zh) 2017-05-10
CN106659738B true CN106659738B (zh) 2021-02-09

Family

ID=53039896

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580029861.5A Active CN106659738B (zh) 2014-04-29 2015-04-29 阿尔茨海默病(ad)的治疗和预防

Country Status (18)

Country Link
US (1) US10478454B2 (enExample)
EP (2) EP3269376B1 (enExample)
JP (1) JP6692755B2 (enExample)
KR (1) KR102388363B1 (enExample)
CN (1) CN106659738B (enExample)
AU (1) AU2015254663B2 (enExample)
CA (1) CA2946928C (enExample)
CY (1) CY1119674T1 (enExample)
DK (1) DK3137093T3 (enExample)
ES (2) ES2824763T3 (enExample)
HR (1) HRP20171896T1 (enExample)
HU (1) HUE037501T2 (enExample)
LT (1) LT3137093T (enExample)
NO (1) NO3137093T3 (enExample)
PL (1) PL3137093T3 (enExample)
PT (1) PT3137093T (enExample)
SI (1) SI3137093T1 (enExample)
WO (1) WO2015165966A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535924A (zh) 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
KR102506460B1 (ko) * 2014-04-29 2023-03-03 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
WO1999027944A1 (en) * 1997-12-02 1999-06-10 Neuralab Limited Prevention and treatment of amyloidogenic disease
CN102834118A (zh) * 2010-03-29 2012-12-19 诺华有限公司 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007040B1 (en) * 1997-08-21 2002-05-08 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
CN106535924A (zh) * 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
KR102506460B1 (ko) * 2014-04-29 2023-03-03 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
WO1999027944A1 (en) * 1997-12-02 1999-06-10 Neuralab Limited Prevention and treatment of amyloidogenic disease
CN102834118A (zh) * 2010-03-29 2012-12-19 诺华有限公司 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice";Heneka et al.;《Nature》;20130131;第493卷(第7434期);第674-681页 *
"Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants";Aimanianda et al.;《Trends in Pharmacological Sciences》;20090511;第30卷(第6期);第287-295页 *

Also Published As

Publication number Publication date
EP3269376A1 (en) 2018-01-17
ES2824763T3 (es) 2021-05-13
AU2015254663A1 (en) 2016-11-10
HRP20171896T1 (hr) 2018-02-23
PL3137093T3 (pl) 2018-06-29
CA2946928A1 (en) 2015-11-05
KR20160145822A (ko) 2016-12-20
ES2651537T3 (es) 2018-01-29
KR102388363B1 (ko) 2022-04-19
DK3137093T3 (en) 2017-12-11
AU2015254663B2 (en) 2020-04-02
CN106659738A (zh) 2017-05-10
SI3137093T1 (en) 2018-01-31
PT3137093T (pt) 2017-12-19
EP3137093B1 (en) 2017-09-13
HUE037501T2 (hu) 2018-08-28
EP3137093A1 (en) 2017-03-08
CY1119674T1 (el) 2018-04-04
JP2017518275A (ja) 2017-07-06
JP6692755B2 (ja) 2020-05-13
CA2946928C (en) 2023-01-31
LT3137093T (lt) 2017-12-11
WO2015165966A1 (en) 2015-11-05
EP3269376B1 (en) 2020-07-15
NO3137093T3 (enExample) 2018-02-10
US20170049812A1 (en) 2017-02-23
US10478454B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
CN106659738B (zh) 阿尔茨海默病(ad)的治疗和预防

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20211020

Address after: Florida, USA

Patentee after: Advantage Medical Co.,Ltd.

Address before: Austria Vienna

Patentee before: AFFIRIS AG